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Abstract
Background: Bardet-Biedl syndrome (BBS) is a heterogeneous human disorder inherited in an autosomal recessive
pattern, and characterized by the primary findings of obesity, polydactyly, hypogonadism, and learning and
behavioural problems. BBS mouse models have a neuroanatomical phenotype consisting of third and lateral
ventriculomegaly, thinning of the cerebral cortex, and reduction in the size of the corpus striatum and
hippocampus. These abnormalities raise the question of whether humans with BBS have a characteristic
morphologic brain phenotype. Further, although behavioral, developmental, neurological and motor defects have
been noted in patients with BBS, to date, there are limited reports of brain findings in BBS. The present study
represents the largest systematic evaluation for the presence of structural brain malformations and/or progressive
changes, which may contribute to these functional problems.
Methods: A case-control study of 21 patients, most aged 13-35 years, except for 2 patients aged 4 and 8 years,
who were diagnosed with BBS by clinical criteria and genetic analysis of known BBS genes, and were evaluated by
qualitative and volumetric brain MRI scans. Healthy controls were matched 3:1 by age, sex and race. Statistical
analysis was performed using SAS language with SAS STAT procedures.
Results: All 21 patients with BBS were found to have statistically significant region- and tissue-specific patterns of
brain abnormalities. There was 1) normal intracranial volume; 2) reduced white matter in all regions of the brain,
but most in the occipital region; 3) preserved gray matter volume, with increased cerebral cortex volume in only
the occipital lobe; 4) reduced gray matter in the subcortical regions of the brain, including the caudate, putamen
and thalamus, but not in the cerebellum; and 5) increased cerebrospinal fluid volume.
Conclusions: There are distinct and characteristic abnormalities in tissue- and region- specific volumes of the brain
in patients with BBS, which parallel the findings, described in BBS mutant mouse models. Some of these brain
abnormalities may be progressive and associated with the reported neurological and behavioral problems. Further
future correlation of these MRI scan findings with detailed neurologic and neuropsychological exams together with
genotype data will provide better understanding of the pathophysiology of BBS.
Background
Bardet-Biedl syndrome (BBS) is a heterogeneous, pleio-
tropic human disorder inherited in an autosomal reces-
sive pattern, and characterized by the primary findings
of obesity, polydactyly, hypogonadism, developmental
delay or learning disabilities, and behavioural problems
[1-3]. Most patients are affected by progressive retinopa-
thy, renal disease, and susceptibility to diabetes mellitus,
hypertension, and congenital cardiac malformations
[1-3]. Currently, the diagnosis of BBS is made on the
basis of clinical criteria [4]. Bardet-Biedl syndrome can
be caused by mutations in as many as 16 genes [5-19].
The majority of proteins encoded by these genes have a
role in the formation, stability and function of cilia [20].
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ing of BBS, it is only in recent years that extensive data
on the natural history and molecular pathogenesis of
this complex disorder have been reported [19].
Individuals with BBS may have cognitive and beha-
vioral phenotypes. While the majority of patients do not
have mental retardation, most cases have an intelligence
quotient (IQ) in the low normal range [2]. Ataxia and
impaired coordination evidenced by impaired tandem
walking, slow repetitive supination/pronation of hands,
and wide based gait were seen in a large patient series
with BBS [4]. Of the 109 patients with BBS, of whom
40% had ataxia with poor coordination and 30% had
gait abnormality, only 10 patients (9%) had brain ima-
ging (CT or MRI), and there were no cerebellar or other
brain abnormalities identified [4]. Moore et al. [3] sug-
gested that the neurological abnormalities of paucity of
facial muscle movement, ataxia and impaired coordina-
tion and mild hypertonia in all four limbs, suggest a
central defect causing impaired coordination, which
affects the brainstem, cerebellar, oculomotor and pyra-
midal tracts. Despite these and other reported neurolo-
gical and behavioural problems in patients with BBS,
there is limited documentation of neuroanatomical
defects by brain imaging.
Analysis of various BBS mouse models confirms that
defective ciliary development is the basis of some BBS
phenotypes. These mice model features of the human
phenotype and also have specific brain and neuroanato-
mical abnormalities [21-26]. The Bbs1
M390R/M390R
knockin mouse model had characteristic features of the
human phenotype, including retinal degeneration, male
infertility, obesity, and olfaction deficits, as did the Bbs2,
Bbs4, and Bbs6 knockout mouse models [27]. Addition-
ally, Bbs1
M390R/M390R m i c eh a v eap r e v i o u s l yu n c h a r a c -
terized neuroanatomical phenotype of ventriculomegaly
involving the third and lateral ventricles, thinning of the
cerebral cortex, and reduction in the size of the corpus
striatum and hippocampus [27].
A review of the literature for reported neuroanatomi-
cal defects in patients with BBS identifies 13 patients
who have abnormal brain findings on neuroimaging
[28-37]. These patients had documented major and
minor findings to confirm a clinical diagnosis of BBS
based upon the published clinical diagnostic criteria
[28-37]. However, only three had testing for the BBS
genes, one of the three had negative testing for 11
genes. Bauman et al. [29] described two patients with
brain abnormalities of gyral atrophy, hydrocephalus,
enlarged cerebral gyri, and hemispheric asymmetry.
Baskin et al. [28] reported one patient with brain
abnormalities of mega cisterna magna, and cerebellar
vermis hypoplasia. Cerebellar atrophy was described in
three separate patients [31,33,34]. Nonspecific cortical
atrophy in one of five patients [37], and temporal and
parietal lobe hypoplasia [30] were found in two patients
with BBS. Soliman et al. [36] reported patients with
empty sella with hypothalamic and pituitary abnormal-
ities. Karmous-Benailly et al. [32] reported two fetuses
with confirmed BBS mutations that were found prena-
tally to have brain abnormalities: Dandy-Walker malfor-
mation in one and agenesis of the corpus callosum in
the other. A recent study of three patients reported evi-
dence of cerebral cortical atrophy, cerebellar atrophy,
lateral ventricle enlargement, temporal and parietal lobe
hyperplasia, and microcephaly [35].
Case series of neuroanatomic abnormalities on clini-
cal scans of patients can be useful in identifying pat-
terns of brain pathology in disorders. However, a
more powerful method of assessing abnormalities in
brain structure is using research MRI scans to obtain
quantitative measures of brain structure in groups of
patients, comparing them to healthy controls. This
technique provides accurate assessment of both global
and regional brain structure. In the past 25 years,
these types of studies in normal healthy populations
have elucidated important information regarding
developmental trajectories and sex differences in both
brain structure and function [38]. Moreover, many
studies have been conducted on patient populations
with brain disorders, including a large number of
developmental syndromes [39]. Although each patient
population has its own unique signature of brain
pathology, important global themes in quantitative
MRI studies of developmental disorders include:
abnormalities in tissue distribution between gray and
white matter with several disorders showing gray mat-
ter or cortical ‘enlargement’ compared to controls
[40-46]; 2) sex-specific morphologic changes
[42,47,48] and 3) alterations in normal growth pat-
terns of brain tissue over time [40].
To date, only one study has used quantitative MRI to
evaluate patients with BBS. Baker et al. [49] recently
reported on 10 patients with BBS compared to 10 con-
trols and found structural abnormalities, including
reduced total gray matter volume, but no total white
matter or cerebrospinal volume changes; gray matter
loss was in the anterior temporal lobes and in the
medial orbitofrontal cortex and white matter volume
loss in the right inferior longitudinal fasciculus [49].
They found regional brain volume loss in the
hippocampus.
Based on the neurological and behavioural problems
reported in patients with BBS, the paucity of brain ima-
ging studies, and neuroanatomical abnormalities found
in BBS mouse models, we conducted a qualitative and
quantitative MRI study to assess brain morphology in
patients with an established diagnosis of BBS.
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Subjects
All 21 subjects were studied at the Clinical Research
Center, National Institutes of Health (NIH) in Bethesda,
MD, USA. The patients were included in the study after
they gave (with their parents if they were minors) writ-
ten informed consent (in accordance with the principles
set forth in US Regulations 45CFR46, which governs
human subjects research in the United States). This
study protocol was approved by both the Institutional
Review Board (IRB) of the National Human Genome
Research Institute (NHGRI), at the National Institutes
of Health (NIH), and by the IRB of the University of
Iowa. The majority of the 21 patients ranged in age
from 13 to 35 years, except for 2 patients aged 4 and 8
years, with 10 males and 11 females (see Table 1 for
demographic information). Recruitment of subjects with
BBS was through referrals from geneticists and genetic
counselors, advertisements in genetics journals, and
through patient support groups. The majority of the
patients with BBS were selected by age (being >12 years)
because of the ability to have a brain MRI scan without
sedation. The diagnosis of BBS was made if the subject
had either four of the six “primary” criteria or at least
three of “primary” criteria, and 2 of the secondary cri-
teria. Mutation analysis was performed in all patients for
the known BBS genes. MKS1 and CEP290 were not ana-
lyzed in this cohort because causation has yet to be con-
firmed for these loci. A BBS gene locus was only
considered causative if a patient had two mutations in
the BBS gene. Whenever possible, both parents were
enrolled for molecular testing for carrier status.
Healthy control subjects were obtained from a data-
base of children and adults who participated in brain
imaging studies at the University of Iowa. This group of
control subjects was chosen to be equivalent in age
(mean and range) and sex composition relative to the
BBS sample. All control subjects were excluded for the
following: major medical, neurological, or psychiatric ill-
ness; previous head trauma; any metal implants.
Image acquisition
For the control subjects, images were obtained at the
University of Iowa on a combination of a 1.5 Tesla GE
Signa MR scanner (n = 53 controls) or a 1.5 Tesla Sie-
mens Avanto Scanner (n = 10 controls). All scans were
obtained using a standard multi-modal protocol that
including axial 3D volumetric spoiled gradient echo ser-
i e s( 1×1×1 . 5m mv o x e l s )a n dad u a le c h op r o t o n
density/T2 (1 × 1 × 3 mm voxels) series. The sequences
have been shown to be comparable across scanners in a
previous study using images obtained on both scanners
[50]. The BBS subjects were scanned at the National
Institutes of Health using a Phillips 1.5T scanner. The
parameters used for the acquisition protocol were
designed to match the sequence obtained at Iowa. This
procedure has been shown to produce comparable
sequences in a previous large, multi-site MRI study [51].
Post processing
All scans were processed through an automated procedure
implemented in BRAINS [52], a family of tools designed
for quantitative brain imaging, validated against manual
tracing. The T1 image was reoriented by stepwise co-regis-
tration to a set of template images, centered on the anterior
commissure, and re-sampled to 1 mm resolution. T2 and
PD images were co-registered to the final T1 image, and all
images were intensity normalized and inhomogeneity cor-
rected. A discriminant tissue classification was then per-
formed and a brain mask was created using an artificial
neural network (ANN). Measures of gray matter, white
matter, and CSF volumes were then completed using the
standard Talairach method. Artificial neural networks were
applied to each scan to measure subcortical structures,
including caudate, putamen, and thalamus. These methods
have been validated with pediatric samples [53]
We studied 21 affected individuals which were
matched by age and sex 1:3 to normal control subjects.
Each scan was evaluated qualitatively by a neuroradiolo-
gist for structural abnormalities.
For this quantitative analysis, a comprehensive exami-
nation of brain structure was done beginning with gen-
eral measures of brain structure compared across
groups including intracranial volume, total brain tissue
volume, cerebellum volume, as well as volumes of tissue
types (cerebrospinal fluid, gray matter, white matter).
Intracranial volume (ICV) is the tissue and fluid within
the calvarium and is a representation of the maximal
brain growth obtained during development [54-56]. In
addition, regional measures of the cerebrum (frontal,
parietal, temporal, and occipital lobes) were also
assessed, as well as volumes of subcortical structures
(caudate, putamen, thalamus). Finally, sex-specific
abnormalities in brain structure were evaluated.
Statistical Analysis
All analyses were performed by using the SAS language
with SAS STAT procedures. All brain measures were
Table 1 Demographic Information on Patients and
Controls
Patients with BBS (n =
21)
Healthy Controls (n =
63)
Age in years (Mean,
S.D.)
21.34, 8.41 18.57, 6.50
Age Range 4.91 - 35.75 7.08 - 35.00
% Male 47.62 47.62
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Brain measures included general measures of intracra-
nial volume (ICV) separated into total Cerebral Spinal
Fluid (CSF) volume and total brain tissue volume. Total
brain tissue was then separated into total white matter
volume and total gray matter volume. Total CSF is sepa-
rated into ventricle volume and ‘surface’ CSF (simple
measure of total CSF minus ventricle volume). Regional
measures included cerebellum tissue volume and cere-
brum measures which were separated into the four cere-
bral lobes (frontal, parietal, temporal, occipital). Each
cerebral lobe was broken down by gray matter and
white matter volumes. Finally, measures of sub-cortical
nuclei (caudate, putamen, and thalamus) were generated.
All measures are reported in cubic centimeters (CC).
For the general measure of ICV, height and sex were
used as covariates. However, to control for differences
in overall head size, all measures were expressed and
analyzed as a proportion of intracranial volume (ICV).
Small structures (caudate, putamen, thalamus), are listed
and labeled as ICV percentages to avoid excessive lead-
ing zeros. All possible interaction terms were entered
into the model, but dropped if not significant. An alpha
level of 0.05 (two-tailed) was used for significance tests.
Results
There were 21 patients with an age range of 13 to 35
years, except for 2 patients aged 4 and 7 years. There
were 10 males and 11 females. All had a clinical diagno-
sis of BBS made by diagnostic criteria [4]. Eighteen
patients had two confirmed causative BBS gene muta-
tions: seven patients with BBS1 mutations (not including
one patient having only one mutation), six patients with
BBS10 mutations, one patient with BBS4 mutations, one
patient with BBS5 mutations, one patient with MKKS
mutations, and one patient with BBS12 mutations.
Three patients did not have identifiable mutations in
BBS1 - BBS12 (we did not assess TRIM32). The control
patient population had the same age range and male/
female distribution.
Qualitative radiological interpretation of the MRI
scans of the brain revealed that ten of 21 patients had
apparently normal studies with no evidence of structural
brain defects, while nine patients had significant find-
ings. These included: two patients with the cerebellar
tonsils ~2 mm below the foramen magnum (one of
which had a likely pineal gland cyst); one with large
pituitary gland and pars intermedia cyst of Rathke’s cleft
cyst; one patient with prominence of the sulci and cere-
bellar folia with normal ventricular system; one patient
with prominent CSF space in the supratentorial part of
the brain; one patient with colpocephaly, hypoplasia of
the hypothalamus/thalamus, and subependymal nodule
with Dandy-Walker variant; one patient with tiny foci of
T2 scattered through the subcortical regions of the cere-
brum and cerebellum; and two patients with mega cis-
terna magna and posterior fossa arachnoid cyst.
The analyses of the quantitative brain measures are
shown in Table 2. For the general brain measures, the
two groups did not differ on ICV. However, subjects
with BBS had substantially smaller total brain tissue
volumes and increased CSF volumes. Within the brain
tissue, gray matter volume did not differ in the two
groups; however white matter was substantially
decreased in volume. Therefore, the decrement in total
brain tissue volume in the BBS subjects appears to be
accounted for primarily by white matter volume loss
while gray matter volume is spared overall. Although
both ventricle volume and surface CSF volume were
both significantly expanded in the subjects with BBS,
this was most robust in the surface CSF measure.
In regional measures, the volume of the cerebral cor-
tex in cases was not significantly different than controls
in the frontal, temporal, or parietal lobes. However, the
volume of the cortex in the occipital lobe was signifi-
cantly increased in the patients with BBS compared to
controls. In regard to white matter, all four cerebral
lobes showed substantial decrements in volume in the
patients with BBS compared to controls. This difference
was largest in the occipital lobe.
The sub-cortical nuclei of caudate, putamen and thala-
mus were all decreased in volume in the patients with
BBS compared to controls. However, the volume of the
cerebellum was not different between the two groups.
Sex effects
Although as a group, the subjects with BBS had no dif-
ferences compared to controls in the gray matter mea-
sures, there were two measures that had significant sex
by group interactions: total gray matter volume and
f r o n t a ll o b eg r a ym a t t e rv o l u m e .T a b l e3s h o w st h e s e
brain measures separated by sex. These analyses show
that although the female subjects with BBS when com-
pared to female controls were not different in these two
measures, the male patients with BBS had significantly
larger gray matter volumes (total and frontal lobe) com-
pared to the male controls.
Discussion
In this study, we present the results of cranial MRI ima-
ging utilizing volumetric analyses of the CNS on 21
patients with the diagnosis of Bardet-Biedl syndrome
c o n f i r m e db yc l i n i c a ld i a g n o s t i cc r i t e r i aa n db yg e n e t i c
testing for the known BBS genes. This represents the
largest case-control study of brain findings in BBS. We
found that there are consistent brain abnormalities in
patients with BBS: 1) normal intracranial volume; 2)
reduced white matter in all regions of the brain, but
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gray matter volume, with increased cerebral cortex
volume in only the occipital lobe; 4) reduced gray mat-
ter in the subcortical regions of the brain, including the
caudate, putamen and thalamus, but not in the cerebel-
lum; 5) increased cerebrospinal fluid volume in both the
surface of the brain and ventricles; and 6) there were
sex differences: the gray matter volume in females with
BBS did not differ from female controls, but that
volume in males with BBS was significantly greater than
male controls. The brain morphological abnormality in
this study of substantially decreased white matter in the
occipital lobe represents a unique observation that has
not been described either in other patients with BBS or
in subjects with isolated or nonsyndromic visual
impairment.
Many of the current findings are consistent with the
previous study by Baker et al. [49], including total brain
volume decrement and global and occipito-temporal
white matter volume decrement. However, there were
some differences in the results of the two studies and
we have extended the findings with novel quantitative
findings. For the Baker study, the white matter volume
did not reach statistical significance however was quan-
tified as a nearly 5% reduction in global white matter
volume. Here we show that this difference is statistically
significant. In contrast to the current findings, the Baker
study found both global and regional gray matter defi-
cits. One possible reason for the difference in findings
in the global gray matter is that the Baker sample was
primarily female and our findings indicate that male
BBS subjects tend to have enlarged cortical volumes.
While the current study found that females with BBS
had smaller volumes of total gray matter, it did not
reach significance. Moreover, the regional deficits
r e p o r t e di nt h eB a k e rs t u d yw e r es m a l l ,f o c a la r e a so f
deficit (gyrus rectus, temporal poles and hippocampus)
w h i l et h ec u r r e n ts t u d ye v a l u ated larger regions (cere-
bral lobes) in which small areas of deficit can remain
undetected. They did not find cerebrospinal volume
Table 2 Analyses of the Quantitative Brain Measures for Patients with BBS and Healthy Controls
Patients with BBS (n = 21) Healthy Controls (n = 63) Sex by Diagnostic Interaction
Adjusted Mean Raw Mean Adjusted Mean Raw Mean F* p F p
ICV (cm
3) 1,399.05 1,394.12 (109.14) 1,396.66 1,393.70 (124.49) 0.01 0.924 2.48 0.119
Total Brain Tissue 0.913 1,269.60 (122.95) 0.948 1,321.96 (115.29) 23.07 <0.0001 0.97 0.327
Gray Matter 0.613 846.53 (88.11) 0.608 849.51 (63.43) 0.68 0.426 4.63 0.034
White Matter 0.299 423.06 (53.47) 0.339 472.45 (66.86) 42.37 <0.0001 0.54 0.463
CSF 0.086 124.45 (51.27) 0.051 71.73 (38.43) 23.07 <0.0001 0.97 0.327
Surface CSF 0.074 106.83 (48.07) 0.042 59.20 (35.03) 21.85 <0.0001 1.09 0.299
Ventricles 0.012 17.62 (7.09) 0.009 12.52 (9.21) 4.15 .0.450 0.00 0.952
Cerebral Cortex
Frontal 0.197 267.92 (31.81) 0.194 268.99 (20.00) 0.55 0.461 5.31 0.023
Temporal 0.124 172.92 (17.86) 0.125 175.02 (14.24) 0.32 0.571 0.05 0.824
Parietal 0.104 143.85 (15.96) 0.105 147.36 (12.35) 0.36 0.551 0.73 0.395
Occipital 0.062 86.59 (9.73) 0.055 77.95 (7.88) 36.41 <0.0001 0.01 0.913
Cerebral White Matter
Frontal 0.107 151.99 (20.70) 0.119 166.92 (24.59) 23.77 <0.0001 1.25 0.266
Temporal 0.042 60.02 (9.79) 0.049 68.60 (10.69) 39.36 <0.0001 0.00 0.963
Parietal 0.069 97.75 (13.99) 0.074 104.52 (15.67) 10.62 0.0016 0.04 0.844
Occipital 0.017 25.25 (5.75) 0.305 42.50 (9.31) 163.30 <0.0001 0.19 0.662
Cerebellum 0.105 145.77 (15.94) 0.103 143.42 (13.06) 1.93 0.168 0.49 0.487
Caudate 0.311 4.29 (0.58) 0.338 4.73 (0.69) 7.44 0.007 0.02 0.882
Putamen 0.776 10.68 (1.51) 0.834 11.63 (1.29) 7.34 0.008 1.53 0.220
Thalamus 0.846 11.79 (1.70) 0.885 12.32 (1.18) 4.77 0.032 2.22 0.139
*ANCOVA: controlling for age and sex; All brain measures (other than ICV) are expressed as volume/ICV ratios. For caudate, putamen and thalamus, measure is
volume/ICV X100 (% of ICV).
Table 3 Effects of Sex on Total Gray Matter and Frontal Lobe Gray Matter Volume*
Males with BBS Control Males t P Females with BBS Control Females t p
Total Gray Matter 0.622 0.606 2.09 0.039 0.604 0.611 0.958 0.346
Frontal Lobe Gray Matter 0.197 0.191 2.14 0.035 0.191 0.194 1.11 0.267
*Represent ratios of total gray matter and frontal lobe gray matter to total intracranial volume (ICV)
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the brain, which is found in this study and supported by
findings in the BBS mouse models. The differences that
were present between our studies may be attributed to
several possible factors: 1) differences in quantitative
MRI scan methodology; 2) their smaller sample size and
control population; and 3) the lack of analysis of sex
effects in their study.
The neuroanatomical abnormalities in the Bbs1
mutant, Bbs
M390R/M390R, mice include ventriculomegaly
involving the third and lateral ventricles, thinning of the
cerebral cortex, and reduction in the size of the subcor-
tical structures such as the corpus striatum and hippo-
campus [27]. In particular, the enlargement of the
lateral ventricles is most severe, whereas the increased
size of the third ventricle is less pronounced. The mod-
erately enlarged lateral ventricles and a reduced corpus
striatum are seen as early as postnatal week three. The
pathology appears to be progressive based on greater
enlargement of the lateral and third ventricles of 3.5 to
6-month-old mutant animals as assessed by coronal
MRI. In addition to ventriculomegaly, the Bbs1
M390R/
M390R mice have thinning of the caudal half of the cere-
bral cortex and a reduction in the size of the corpus
striatum and hippocampus. These neuroanatomical
defects were also noted in the Bbs2
-/-,B b s 4
-/- ,B b s 6
-/-
mice of comparable ages. There is no enlargement of
the fourth ventricle in any of these mouse models.
Neither the current study nor the previous study by
Baker et al. [49] found evidence of ventriculomegaly in
humans with BBS. However, we did indeed find reduc-
tion in the volume of the striatum, suggesting that the
mouse models the human in this respect.
Intracranial volume or ICV is a measure of maximal
brain growth; it is the volume of the internal skull cavity
and is determined by brain growth, which peaks around
the age of 12 years [54-56]. The fact that the subjects
with BBS had normal ICV suggests that their maximal
point of brain growth was no different than that of the
controls. However, their total tissue volume was sub-
stantially decreased suggesting that some brain process
after peak growth had decreased the volume of their
brain. Because the previous tissue composition was not
measured, we cannot assess the processes that led to
decreased tissue. Possibilities include a lack of myelina-
tion (normally myelin is laid down until the 3
rd,e v e n
4
th decade of life) or demyelination; another possibility
is excess pruning which happens normally in adoles-
cence, but that would suggest that the cortex started out
enlarged and was normal size when the patients were
scanned. Another possibility is atrophy with frank cell
death. The CSF space enlargement is also supportive of
the notion that there is fluid where tissue once was -
supporting the hypothesis that there was loss of cerebral
tissue. There was no evidence of obstructive hydroce-
phalus due to aqueductal stenosis based upon clinical
findings of absent normal fourth ventricle size and nor-
mocephaly. Consistent with the findings of progressive
tissue loss after development, the Bbs1 mutant mice
brains showed progressive pathology based on the
greater enlargement of the lateral and third ventricles of
3.5- to 6-month-old mutant animals as assessed by cor-
onal MRI [27].
The regional structural abnormalities in this study are
important to highlight as well, to consider the potential
functional correlations. One of the most significant find-
ings was that of cortical enlargement and white matter
reduction in the occipital lobe. This abnormality did not
have a sex effect and thus was evident in the whole
group. This finding suggests a functional correlate since
most subjects in the study had progressive retinal
degeneration with vision loss. The observation of white
matter loss in the occipital lobe in other forms of reti-
nopathy has not been described in the literature from
our review. As one of the major functions of the occipi-
tal cortex is visual processing, we hypothesize that
patients with BBS have a compensatory increase in occi-
pital cortex because of progressive visual loss. There is
little available published data in both the mouse models
and human studies regarding brain morphology and
visual loss, in particular regional cortical brain analyses.
However, there are two reports, which describe analyses
of the visual cortex in humans with early- and late-
onset blindness. This study found that the bilateral
visual cortices of the blind were thicker than those
sighted controls, which may support the hypothesis that
sensory experience is necessary for appropriate regres-
sion and remodeling of neuronal processes and that
synaptic regression might be a major determinant of
macroscopic anatomical features like cortical thickness.
It has been found that pruning of the synapses depends
on visual input. Therefore, these studies support our
finding of increase in the volume of the occipital cortex
since all our patients had evidence of rod-cone dystro-
phy [[57],58]. Another finding of the entire group with
n os e xe f f e c ti si nt h er e d u c t i o no ft h es t r i a t u mw h i c h
could be related to the motor abnormalities seen in
patients with BBS such as slow supination/pronation
and poor tandem walking. This may be particularly rele-
vant to the fact that the cerebellum in both the current
study and in the Baker study was found to be structu-
rally normal, suggesting that these motor abnormalities
may not be related to a primary cerebellum dysfunction.
Finally, the regional abnormality of enlarged frontal
lobe volume in the male subjects with BBS is an inter-
esting and somewhat unexpected finding. The pattern of
a developmental syndrome having cortical enlargement
is not uncommon, being reported in a variety of
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Syndrome [43], autism [44], neurofibromatosis [41],
Attention Deficit Disorder [45], and Williams Syndrome
[46]. In oral clefting, the cortical enlargement was seen
only in males and was directly related to cognitive and
behavioral abnormalities of inattention and hyperactivity
[57]. Although sex-specific abnormalities in cognition
and behavior in BBS has not been reported, studies in
the future should evaluate the patterns of cognitive and
behavioral abnormalities and relate them to structural
abnormalities such as seen here in the current study.
The current study has several limitations that should
be considered. First, there were several different scan-
ners used across the various groups (both BBS and con-
trols). Although validation studies have shown the
measures produced from these scanners to be compar-
able, a potential confounder would be created if indeed
measures differed between scanners. Also, the age range
of both groups varied widely. Although the control
group had sex and age appropriate subjects, evaluation
of age and developmental effects can’t be adequately
addressed, given the small sample size of the BBS sub-
jects and the non-normal distribution of ages (in the
BBS sample, over half of the sample was 20 years of age
and over and only 2 subjects were below the age of 12).
Future directions would include expanding the study to
include more subjects in the younger age ranges (below
18 years).
Conclusions
We conducted a case-control study comparing the brain
findings in patients with Bardet-Biedl syndrome to a
matched control population. There were distinct and
characteristic abnormalities in tissue- and region- speci-
fic volumes of the brain, which correspond to several
findings, described in BBSm u t a n tm o u s em o d e l s .W e
identified novel and different quantitative brain abnorm-
alities, extending those findings described in the Baker
study [49]. We show that there is a statistically signifi-
cant difference in the white matter volume in patients
with BBS, with cortical enlargement in the occipital
lobe. There was preserved total gray matter volume in
our sample, including the cerebellar region, which was
controlled for not only age differences but also sex dif-
ferences. Contrasting with the Baker study, we found
decreased cerebrospinal volume and gray matter loss in
the subcortical regions of the brain, which mirrors the
neuroanatomical findings in the BBS mouse models. In
addition, the results of this study indicate that some of
these brain abnormalities may be progressive indicated
by preserved intracranial volume between the controls
and BBS patients accompanied by substantially smaller
total brain tissue volumes, in addition to associated neu-
rological and behavioral problems reported in patients
with BBS. While the use of quantitative MRI scan is
useful on a research basis, these data do not suggest
that MRIs are clinically indicated for BBS. Future studies
to correlate these MRI findings with detailed neurologic
and neuropsychological examinations and genotype data
will provide better understanding of the pathophysiology
of BBS.
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